Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. Recordati
  6. News
  7. Summary
    REC   IT0003828271

RECORDATI

(REC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

RECORDATI: PUBLIC DISCLOSURE

07/30/2021 | 09:59am EDT

NEWS RELEASE

RECORDATI: PUBLIC DISCLOSURE

Milan, 30thJuly 2021 - Following the press release issued on date 29th July 2021, please be informed that the Interim financial statements at 30th June 2021, approved yesterday by the Board of Directors, and the Independent Auditors' Report on the interim condensed consolidated financial statements at 30th June 2021 are available to the public, as of today, at the Company's registered office, on the Company's website (www.recordati.com) and on the "1INFO" storage mechanism (www.1info.it).

Recordati (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a specialised business dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was €1,448.9 million, operating income was €469.0 million and net income was €355.0 million.

Further information:

Recordati website: www.recordati.it

Investor Relations

Media Relations

Federica De Medici

Studio Noris Morano

(39) 02 48787146

(39) 02 76004736, (39) 02 76004745

e-mail: investorelations@recordati.it

e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered office VIA M. CIVITALI, 1 20148 MILAN, ITALY TEL. +39 0248787.1 FAX +39 0240073747

SHARE CAPITAL € 26,140,644.50 fully paid up

BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI 00748210150

TAX CODE/VAT NO. 00748210150

Company subject to management and coordination by Rossini Luxembourg S.àr.l

Disclaimer

Recordati S.p.A. published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 13:58:05 UTC.


© Publicnow 2021
All news about RECORDATI
10/15STOXX EUROPE 600 : Italy's ITA Seeks to Join Airline Pact in 2022
MT
10/15AIR FRANCE KLM : Alitalia successor ITA wants to join a strategic alliance, says chairman
RE
10/11RECORDATI : Resignation of a non-executive director
PU
10/11RECORDATI : 2022 corporate events' calendar
PU
07/30RECORDATI : Public disclosure
PU
07/29Recordati Industria Chimica E Farmaceutica S.P.A. Reports Earnings Results for the Half..
CI
07/29Recordati Revises Revenue Guidance for the Full Year of 2021
CI
07/29RECORDATI : Confirms 2021 Guidance
MT
07/29RECORDATI : First half of 2021 results approved, revenue +1.4%, ebitda -3.4%, net income +..
PU
07/16RECORDATI : CEO to Transition to Chairman Role, Successor CEO Named
MT
More news
Analyst Recommendations on RECORDATI
More recommendations
Financials
Sales 2021 1 587 M 1 849 M 1 849 M
Net income 2021 410 M 478 M 478 M
Net Debt 2021 788 M 918 M 918 M
P/E ratio 2021 27,1x
Yield 2021 2,14%
Capitalization 10 777 M 12 535 M 12 552 M
EV / Sales 2021 7,29x
EV / Sales 2022 6,72x
Nbr of Employees 4 446
Free-Float 46,6%
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 52,48 €
Average target price 49,21 €
Spread / Average Target -6,23%
EPS Revisions
Managers and Directors
Andrea Recordati Chief Executive Officer
Luigi Felice la Corte Group Chief Financial Officer
Alfredo Altavilla Chairman
Raffaele Sabia Senior VP-Pharmaceutical Research & Development
Michaela Castelli Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RECORDATI15.77%12 535
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
PFIZER, INC.16.27%240 303
NOVO NORDISK A/S56.55%239 079
ELI LILLY AND COMPANY42.84%218 640